Low-Dose Triptolide Enhanced Activity of Idarubicin Against Acute Myeloid Leukemia Stem-like Cells Via Inhibiting DNA Damage Repair Response
- 19 October 2020
- journal article
- research article
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 17 (2) , 616-627
Abstract
Leukemia stem cells (LSCs) are considered to be the root of relapse for acute myeloid leukemia (AML). Conventional chemotherapeutic drugs fail to eliminate LSCs. Therefore, new therapeutic strategies eliminating LSCs are urgently needed. Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1αand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells. Inspiringly, the combination treatment with low-dose TPL and IDA was also effective against CD34 + blasts from AML patients with FLT3-ITD mutation, which is an unfavorable risk factor for AML patients. Moreover, the combination of TPL and IDA induced a remarkable suppression of human leukemia growth in a xenograft mouse model. Mechanistically, the enhanced effect of low dose TPL on IDA against LSCs was attributed to inhibiting DNA damage repair response. Thus, our study may provide a theoretical basis to facilitate the development of a novel LSCs-targeting strategy for AML. Graphical abstractKeywords
Funding Information
- National Natural Science Foundation of China (No.81570156, No.81570425, N0. 81770126)
- Excellent Young Scientists Fund (N0. 81700156)
This publication has 34 references indexed in Scilit:
- IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in CancerMolecular Cell, 2019
- Hematopoietic stem cell transplantation for acute myeloid leukemiaHematology/Oncology and Stem Cell Therapy, 2017
- The DNA damage response pathway in normal hematopoiesis and malignanciesInternational Journal of Hematology, 2017
- Mechanisms of DNA damage, repair, and mutagenesisEnvironmental and Molecular Mutagenesis, 2017
- Biology and relevance of human acute myeloid leukemia stem cellsBlood, 2017
- DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppressionCarcinogenesis, 2017
- ‘Acute myeloid leukemia: a comprehensive review and 2016 update’Blood Cancer Journal, 2016
- DNA damage response – A double-edged sword in cancer prevention and cancer therapyCancer Letters, 2015
- Chemotherapy induced DNA damage responseCancer Biology & Therapy, 2013
- Repair of idarubicin-induced DNA damage: A cause of resistance?DNA Repair, 2007